Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin vs Lactulose in Cirrhotic Patients with Renal Failure
NCT00748904Phase 4Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin in hepatic encephalopathy (HE), sponsored by Weill Cornell Medicine. Planned start Jun 2008; status: withdrawn.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT00748904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748904.